Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses

Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414, and 1074383, as well as infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry. We thank the Herbert Irving Comprehensive Cancer Center (P30CA013696) Database Shared Resource for providing clinical data and biospecimens to facilitate the project. This article is based, in part, upon work from COST Action Precision-BTC Network, CA22125, supported by COST (European Cooperation in Science and Technology). PLCO is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, and contracts from the Division of Cancer Prevention, NCI, NIH, DHHS. The authors thank the NCI study management team, the screening center investigators, and staff at Information Management Services, Inc., and Westat, Inc. Most importantly, we thank the study participants for their contributions that made this study possible. Cancer incidence data were provided by the Colorado Central Cancer Registry, District of Columbia Cancer Registry, Georgia Cancer Registry, Hawaii Cancer Registry, Cancer Data Registry of Idaho, Minnesota Cancer Surveillance System, Missouri Cancer Registry, Nevada Central Cancer Registry, Pennsylvania Cancer Registry, Texas Cancer Registry, Virginia Cancer Registry, and Wisconsin Cancer Reporting System. All are supported in part by funds from the Centers for Disease Control and Prevention, National Program for Central Registries, local states, or by the National Cancer Institute, Surveillance, Epidemiology, and End Results program. The results reported here, and the conclusions derived, are the sole responsibility of the authors. This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH authors are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the authors and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services. The authors would like to acknowledge the European Network for the Study of Cholangiocarcinoma (ENS-CCA) for their support. We also acknowledge the National Cancer Institute Collaboration Agreement for Genomic Studies for providing the resources essential to the genomic analysis in this study (NCI Ref.#42658-17, NCI PI Katherine A McGlynn and Mayo Clinic PI Lewis R. Roberts).